Currently out of the existing stock ratings of James Edwardes Jones, 10 are a HOLD (16.67%), 47 are a BUY (78.33%), 3 are a SELL (5%).

James Edwardes Jones

Work Performance Price Targets & Ratings Chart

Analyst James Edwardes Jones works at RBC with a stock forecast success ratio of 33.9% fulfilled within 56.33 days on average. Previously, James Edwardes Jones worked at OPPENHEIMER.

James Edwardes Jones’s has documented 109 price targets and ratings displayed on 18 stocks. The coverage is on Consumer Defensive, Healthcare sectors.

Most recent stock forecast was given on PLRX, Pliant Therapeutics at 10-Aug-2023.

Wall Street Analyst James Edwardes Jones

Analyst best performing recommendations are on CYCC (CYCLACEL PHARMACEUTICALS).
The best stock recommendation documented was for CYCC (CYCLACEL PHARMACEUTICALS) at 3/7/2023. The price target of $10 was fulfilled within 3 days with a profit of $0.93 (8.51%) receiving and performance score of 28.36.

Average potential price target upside

of $15.32 (31.99%) on RXDX (PROMETHEUS BIOSCIENCES).
of $14.78 (75.87%) on VTYX (VENTYX BIOSCIENCES).
of $14.27 (197.02%) on CRBP (CORBUS PHARMACEUTICALS).

BTI British American Tobacco p.l.c. BUD Anheuser Busch Inbev NV ADR DEO Diageo PLC ADR UL Unilever PLC ADR RXDX Prometheus Biosciences CMMB Chemomab Therapeutics Ltd DRC CYCC Cyclacel Pharmaceuticals EVAX Evaxion Biotech AS MBRX Moleculin Biotech PDRDY Pernod Ricard SA PLRX Pliant Therapeutics PMVP Pmv Pharmaceuticals UN Unilever PLC VTYX Ventyx Biosciences NOVN Novan CRBP Corbus Pharmaceuticals PNT POINT Biopharma Global RAIN Rain Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Owen Bennett (JEFFERIES)